Consideration of Ayahuasca for the Treatment of Post-traumatic Stress Disorder Jessica L. NIELSON, & Julie D. MEGLER MAPS Bulletin Annual Report, Winter 2012, 29-31. THERE IS A GROWING AMOUNT OF RESEARCH on the development of PTSD and its various treatments. The fact that many people who su!er from PTSD struggle with the currently approved therapeutic options that are available to them suggests that we need to start exploring alternative strategies to treat this disorder.1 With the large number of veterans returning home from war that may have or will develop PTSD, we must have a diverse framework of therapy and integration in place [...]
Lire la suiteEndocannabinoid signaling in psychiatric disorders: a review of positron emission tomography studies Matthew E. Sloan, Caroline W. Grant, Joshua L. Gowin, Vijay A. Ramchandani and Bernard Le Foll Acta Pharmacologica Sinica, 2018, 0, 1–9; https://doi.org/10.1038/s41401-018-0081-z Endocannabinoid signaling is implicated in an array of psychopathologies ranging from anxiety to psychosis and addiction. In recent years, radiotracers targeting the endocannabinoid system have been used in positron emission tomography (PET) studies to determine whether individuals with psychiatric disorders display altered endocannabinoid signaling. We comprehensively reviewed PET studies examining differences in endocannabinoid signaling between individuals with psychiatric illness and healthy controls. Published studies evaluated individuals with five psychiatric [...]
Lire la suiteFrom experimental psychosis to resolving traumatic pasts - Psychedelic Research in Communist Czechoslovakia, 1954‑1974 De la psychose expérimentale à la guérison des traumatismes du passé : la recherche psychédélique en Tchécoslovaquie communiste, 1954‑1974 Sarah Marks Cahiers du monde russe, 2015, 56, 1, 53-75. DOI: 10.4000/monderusse.8165 The mid‑twentieth century saw an abundance of new theories of human behaviour and mental disorder, many of which were inspired by new developments in broader scientific fields, from cybernetics and genetics, to pharmaceuticals and new technologies of psychological testing1. There is a developing historical literature on the development of psychiatry in Western Europe and North America, yet we know little [...]
Lire la suitePsychedelic microdosing benefits and challenges : an empirical codebook Thomas Anderson, Rotem Petranker, Adam Christopher, Daniel Rosenbaum, Cory Weissman, Le-Anh Dinh-Williams, Katrina Hui, Emma Hapke Harm Reduction Journal, 2019. Doi : 10.1186/s12954-019-0308-4 Abstract Background : Microdosing psychedelics is the practice of consuming very low, sub-hallucinogenic doses of a psychedelic substance, such as lysergic acid diethylamide (LSD) or psilocybin-containing mushrooms. According to media reports, microdosing has grown in popularity, yet the scientific literature contains minimal research on this practice. There has been limited reporting on adverse events associated with microdosing, and the experiences of microdosers in community samples have not been categorized. Methods : In the present study, [...]
Lire la suiteReduction in social anxiety after MDMA-assisted psychotherapy with autistic adults : a randomized, double-blind, placebo-controlled pilot study Alicia L. Danforth, Charles S. Grob, Christopher Struble, Allison A. Feduccia, Nick Walker, Lisa Jerome, Berra Yazar-Klosinski & Amy Emerson Psychopharmacology, 2018, https://doi.org/10.1007/s00213-018-5010-9 Abstract Rationale : Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4- methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. Objectives : To explore feasibility and safety ofMDMA-assisted psychotherapy for reduction of social fear and avoidance that are common in the autistic population. Methods : Autistic adults with marked to [...]
Lire la suiteThe LSD Therapy Career of Jan Bastiaans, M.D. Stephen Snelders Newsletter of the Multidisciplinary Association for Psychedelic Studies, MAPS : 1998, Vol 8, N° 1, pp. 18-20 JAN BASTIAANS WAS 23 YEARS OLD and a medical student at the University of Amsterdam when the German army invaded the Netherlands. The German occupation (1940-1945) had a lasting influence on his life and work. The first aim of Bastiaans' use of LSD and psilocybin in psychotherapy was to help victims of World War II: the survivors of the war who had become extremely traumatized by their experiences in the German and Japanese prisons and concentration [...]
Lire la suiteChronic, Intermittent Microdoses of the Psychedelic N,N‑Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents Lindsay P. Cameron, Charlie J. Benson, Brian C. DeFelice, Oliver Fiehn, and David E. Olson ACS Chemical Neurosciences, 2019 DOI: 10.1021/acschemneuro.8b00692 ABSTRACT : Drugs capable of ameliorating symptoms of depression and anxiety while also improving cognitive function and sociability are highly desirable. Anecdotal reports have suggested that serotonergic psychedelics administered in low doses on a chronic, intermittent schedule, so-called “microdosing”, might produce beneficial effects on mood, anxiety, cognition, and social interaction. Here, we test this hypothesis by subjecting male and female Sprague Dawley rats to behavioral testing following the [...]
Lire la suiteThe tripping point : The potential role of psychedelic-assisted therapy in the response to the opioid crisis Elena Argento, Kenneth W. Tupper, M. Eugenia Socias International Journal of Drug Policy, 2019, 66, 80–81 https://doi.org/10.1016/j.drugpo.2018.11.006 0955-3959/ © 2018 Elsevier B.V. All rights reserved A B S T R A C T The increasing contamination of the drug supply with illicitly manufactured fentanyl and related analogs in North America has resulted in the most severe drug-overdose crisis in history. Available pharmaco-therapy options for the treatment of opioid use disorder have had limited success in curbing the current crisis, and a growing body of evidence highlights the need for [...]
Lire la suitePotential Psychiatric Uses for MDMA B.B. Yazar-Klosinski and M.C. Mithoefer CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101, 2 www.wileyonlinelibrary/cpt doi:10.1002/cpt.565 Phase II trials of 3,4-methylenedioxymethamphetamine (MDMA)- assisted psychotherapy have demonstrated initial safety and efficacy for treatment of posttraumatic stress disorder (PTSD), with potential for expansion to depression and anxiety disorders. In these trials, single doses of MDMA are administered in a model of medication-assisted psychotherapy, differing from trials involving daily drug administration without psychotherapy. This model presents an opportunity to utilize accelerated regulatory pathways, such as the US Food and Drug Administration (FDA) Breakthrough Therapy Designation, to most effectively and expeditiously test such novel approaches. BACKGROUND MDMA-assisted [...]
Lire la suitePrescribing Health Care Providers’ Attitudes, Experiences, and Practices Surrounding Cannabis Use in Patients with Anxiety Disorders and Post-Traumatic Stress Disorder Jake Rosenberg, Mallory J.E. Loflin, Yasmin L. Hurd, and Marcel O. Bonn-Miller Cannabis and Cannabinoid Research, 2019, Volume 4, Number 2, DOI: 10.1089/can.2018.0008 Abstract Background : Preliminary evidence suggests that certain cannabinoids may be beneficial for the treatment of anxiety and post-traumatic stress disorder (PTSD). However, it is unclear whether prescribing health care professionals view medicinal cannabis as a safe and effective option for treatment of these disorders. Methods : Three hundred fifty-two prescribing health care professionals across the United States completed an online survey assessing [...]
Lire la suite